Ipamorelin: The Complete Guide (2026)

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide — composed of five amino acids — classified as a growth hormone secretagogue. It belongs to the family of growth hormone releasing peptides (GHRPs) and was first described in the research literature in the late 1990s. Among the various GHRPs studied to date, Ipamorelin is widely regarded as one of the mildest and most selective.

Unlike broader-acting growth hormone secretagogues, Ipamorelin is notable for its ability to stimulate growth hormone (GH) release from the pituitary gland without significantly elevating cortisol, prolactin, or other hormones that many GHRPs tend to affect. This selectivity has made it one of the most popular peptides in the research community.

Ipamorelin is classified as a research peptide and is not approved by the FDA for any medical use. It is commonly studied alongside CJC-1295, a growth hormone releasing hormone (GHRH) analog, as the two peptides appear to work through complementary pathways.

How Does Ipamorelin Work?

Ipamorelin exerts its effects primarily through the ghrelin receptor (also known as the growth hormone secretagogue receptor, or GHS-R). Understanding its mechanism helps explain why it is considered the cleanest GHRP available.

Ghrelin Receptor Agonism

Ipamorelin acts as a ghrelin receptor agonist, binding to GHS-R1a receptors located on somatotroph cells in the anterior pituitary gland. This binding triggers a signaling cascade that stimulates the release of stored growth hormone into the bloodstream. The GH release occurs in a pulsatile manner, closely mimicking the body's natural secretion pattern.

Selective GH Release

What sets Ipamorelin apart from other GHRPs is its selectivity. Published research indicates that Ipamorelin stimulates GH release in a dose-dependent manner without causing significant increases in cortisol, ACTH (adrenocorticotropic hormone), or prolactin at typical research dosages. This is in contrast to peptides like GHRP-6 and Hexarelin, which tend to activate broader hormonal responses.

Dose-Dependent GH Elevation

Studies suggest that Ipamorelin produces a clean, dose-dependent increase in plasma growth hormone levels. This means that GH output rises proportionally with dosage up to a saturation point, without the hormonal side effects associated with less selective secretagogues. Research indicates peak GH levels are typically reached within 30–45 minutes of administration.

Does Not Suppress Natural Production

Unlike exogenous growth hormone (synthetic HGH), Ipamorelin works by stimulating the pituitary to release its own GH stores. This means the body's natural GH production and feedback mechanisms remain intact. The pituitary is still subject to normal regulatory signals from somatostatin, which helps prevent supraphysiological GH levels.

Ipamorelin vs Other GH Peptides

Several growth hormone releasing peptides have been studied over the years. Below is a comparison of Ipamorelin to the other commonly discussed GHRPs, based on published research findings.

Ipamorelin vs GHRP-6

GHRP-6 was one of the earliest GHRPs studied and is known for producing strong GH release. However, GHRP-6 also significantly stimulates appetite (via ghrelin pathway activation) and may elevate cortisol and prolactin levels. Ipamorelin provides comparable GH elevation without the intense hunger or the cortisol and prolactin spikes, making it the preferred choice for researchers seeking a cleaner hormonal profile.

Ipamorelin vs GHRP-2

GHRP-2 is considered more potent than GHRP-6 in terms of raw GH output per microgram. It also stimulates appetite, though generally less aggressively than GHRP-6. GHRP-2 can elevate cortisol and prolactin at higher dosages. Ipamorelin is milder in overall GH output compared to GHRP-2 but maintains its advantage in selectivity — researchers who prioritize a clean side-effect profile often prefer Ipamorelin.

Ipamorelin vs Hexarelin

Hexarelin is the most potent GHRP in terms of peak GH release. However, it comes with the most pronounced side effects among the GHRPs, including notable cortisol and prolactin elevation. Hexarelin is also associated with rapid desensitization of the GHS receptor with continued use, meaning its effectiveness may diminish over time. Ipamorelin shows significantly less desensitization in published research and maintains its clean profile.

Why Ipamorelin Is Considered the Cleanest GHRP

To summarize, Ipamorelin occupies a unique position among GHRPs: it provides meaningful GH elevation with minimal impact on cortisol, prolactin, appetite, and other hormonal markers. While it may not produce the highest absolute GH spike of any GHRP, its selectivity and tolerability make it the most widely recommended starting point for researchers new to growth hormone secretagogues.

Ipamorelin + CJC-1295 Stack

The combination of Ipamorelin and CJC-1295 (particularly the DAC-free variant, often called Modified GRF 1-29) is one of the most widely discussed peptide stacks in the growth hormone research space. Understanding why these two peptides are frequently paired requires a look at their complementary mechanisms.

Why They Work Together

Ipamorelin (a GHRP) and CJC-1295 (a GHRH analog) operate through different receptors and pathways. CJC-1295 acts on the GHRH receptor to amplify the growth hormone releasing signal, while Ipamorelin acts on the ghrelin receptor to trigger GH release and suppress somatostatin (the hormone that inhibits GH secretion). When used together, the two peptides may produce a synergistic effect — research suggests the combined GH output can be significantly greater than either peptide used alone.

Synergistic GH Release

Published data indicates that combining a GHRH analog with a GHRP can amplify GH release beyond what would be expected from a simple additive effect. The GHRH component primes the pituitary for release while the GHRP provides the triggering signal. This synergy is one of the primary reasons the Ipamorelin + CJC-1295 stack is so popular among researchers.

Common Stack Protocols

In the research community, the Ipamorelin + CJC-1295 (no DAC) stack is commonly discussed at dosages of 100–300mcg of each peptide, administered together 2–3 times daily. Timing is typically on an empty stomach, with the most frequently cited windows being upon waking, post-workout, and before bed. As with all research peptide protocols, this has not been validated through clinical trials.

For a detailed breakdown of CJC-1295, including the differences between the DAC and no-DAC variants, see our CJC-1295 Complete Guide.

Potential Benefits

The following potential benefits are based on published preclinical research and community reports. Human clinical trials specific to Ipamorelin are limited, and these should not be interpreted as guaranteed outcomes.

Growth Hormone Elevation

The primary studied effect of Ipamorelin is its ability to stimulate the pulsatile release of growth hormone from the anterior pituitary. Research indicates this elevation occurs in a dose-dependent, selective manner without disrupting other hormonal axes. Elevated GH levels are associated with a broad range of physiological processes related to growth, repair, and metabolism.

Recovery & Repair

Growth hormone plays a well-established role in tissue repair and recovery. By elevating endogenous GH levels, Ipamorelin may indirectly support the body's natural recovery processes. Community reports frequently cite improved recovery from exercise and physical activity as a primary observed benefit, though controlled human data is lacking.

Sleep Quality

GH secretion is closely linked to deep sleep (slow-wave sleep), with the largest natural GH pulse occurring during the first phase of deep sleep each night. Many researchers and community members report improved sleep quality when using Ipamorelin, particularly when dosed before bedtime. This is consistent with the known relationship between GH and sleep architecture, though it has not been formally studied in clinical trials with Ipamorelin specifically.

Body Composition

Growth hormone is known to influence body composition by promoting lipolysis (fat breakdown) and supporting lean tissue. Some community reports describe modest improvements in body composition over extended research periods with Ipamorelin, including reduced body fat and improved muscle tone. These reports are anecdotal and have not been validated in controlled human studies.

Anti-Aging & Skin Health

GH levels naturally decline with age, a process sometimes referred to as somatopause. By stimulating endogenous GH release, Ipamorelin is of interest to researchers studying age-related GH decline. Some community reports mention improvements in skin elasticity, hair quality, and overall sense of vitality, though these observations remain anecdotal.

Dosage Guidelines

Disclaimer: The following information is based on protocols described in published research literature and community reports. This is not medical advice. Always consult a healthcare professional before using any research compound.

Common Research Protocols

In the research community, Ipamorelin dosage is most commonly discussed in the range of 200mcg to 300mcg per administration, taken 2–3 times daily. This places the total daily dosage between 400mcg and 900mcg, depending on the protocol. Some researchers start at the lower end (100–200mcg) to assess individual response before adjusting upward.

Timing & Meal Considerations

Timing is considered important with Ipamorelin, as fats and carbohydrates can blunt the GH response. Most protocols recommend administering Ipamorelin on an empty stomach — at least 30 minutes before eating or 2 hours after a meal. The three most commonly cited dosing windows are:

• Morning: Upon waking, before breakfast
• Post-workout: After training, before the post-workout meal
• Before bed: The most popular single-dose timing, to amplify the natural nighttime GH pulse

Cycling

While Ipamorelin does not appear to cause significant receptor desensitization in published research, many researchers still follow cycling protocols. Common approaches include 8–12 weeks on followed by 4 weeks off, or 5 days on and 2 days off. Cycling is generally recommended as a precautionary measure, though optimal protocols have not been established through clinical trials.

Administration Route

Ipamorelin is most commonly administered via subcutaneous injection, typically into the abdominal area or thigh. It is supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before use.

How to Reconstitute Ipamorelin

Ipamorelin typically ships as a lyophilized (freeze-dried) powder in a sealed vial. Reconstitution is the process of adding a sterile solvent to prepare it for use. Here is the standard protocol:

What You Need

• Ipamorelin lyophilized vial (commonly 2mg or 5mg)
• Bacteriostatic water (BAC water)
• Insulin syringes (1ml / 100 unit)
• Alcohol swabs

Step-by-Step Reconstitution

1. Clean the vial tops: Wipe the rubber stoppers of both the Ipamorelin vial and the bacteriostatic water vial with alcohol swabs.
2. Draw the BAC water: Using an insulin syringe, draw your desired amount of bacteriostatic water. For a 5mg vial, 2.5ml of BAC water is a common choice, which yields 200mcg per 0.1ml (10 units on the syringe).
3. Add water slowly: Insert the needle into the Ipamorelin vial and let the water drip down the side of the glass. Do not spray directly onto the powder, as this can damage the peptide.
4. Gently swirl: Once the water is added, gently swirl the vial until the powder is fully dissolved. Do not shake vigorously.
5. Store properly: Reconstituted Ipamorelin should be stored in the refrigerator (2–8°C). Most sources recommend using it within 3–4 weeks after reconstitution.

Dosage Math Example

If you reconstitute a 5mg vial with 2.5ml of BAC water:

• 5mg / 2.5ml = 2mg per ml = 2,000mcg per ml
• 200mcg dose = 0.1ml = 10 units on an insulin syringe
• 300mcg dose = 0.15ml = 15 units on an insulin syringe
• One 5mg vial at 200mcg 3x/day = ~8 days of use

Side Effects & Safety

Ipamorelin is widely regarded as one of the best-tolerated growth hormone releasing peptides, largely due to its selectivity and minimal impact on non-GH hormones. However, as with all research compounds, it is important to understand the potential risks.

What Research Shows

In published preclinical studies, Ipamorelin has demonstrated a favorable safety profile. Its selectivity for GH release — without significant cortisol, prolactin, or ACTH elevation — is one of the primary reasons it is considered the mildest GHRP. Comprehensive long-term human safety data from large-scale clinical trials is currently lacking.

Commonly Reported Side Effects

Based on community reports (not clinical data), the most commonly mentioned side effects include:

• Mild head rush or lightheadedness shortly after injection
• Temporary water retention, particularly in the first few weeks
• Tingling or numbness in the hands and feet (a common side effect of elevated GH)
• Mild hunger increase (less pronounced than GHRP-6 or GHRP-2)
• Tiredness or lethargy, especially with evening dosing

Important Safety Considerations

• Not FDA-approved: Ipamorelin is not approved for human use by the FDA or any other regulatory body. It is sold as a research chemical.
• Limited human data: Most safety data comes from preclinical studies. The long-term effects in humans are not well established.
• GH-related risks: Sustained elevation of growth hormone can theoretically promote the growth of existing tumors or contribute to joint pain and carpal tunnel symptoms. These risks are generally associated with supraphysiological GH levels from exogenous HGH rather than the modest elevations from secretagogues, but they warrant consideration.
• Potential interactions: The effects of Ipamorelin in combination with other compounds or medications have not been thoroughly studied in controlled settings.
• Quality control: As a research peptide, product quality can vary significantly between vendors. Third-party testing is essential.

Where to Buy Ipamorelin

Sourcing high-quality Ipamorelin is critical. The research peptide market includes vendors of varying quality, and purchasing from an unreliable source can mean receiving underdosed, degraded, or contaminated product. Here are our top recommended vendors for 2026, evaluated on purity, third-party testing, pricing, and customer service.

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. This helps support our independent research and content. We only recommend vendors we have vetted and trust.

Frequently Asked Questions